One study found that structurally distinct MEK inhibitor tool compounds (U0126, MIIC, PD98059) impair ETS Complex I activity in HL-60 cells.(62) Here we demonstrated that the first-in-class MEK inhibitor therapeutic Trm compromises oxidative metabolism in some, but not all, cancer cell types and that this effect is not dependent on the BRAF V600E oncogenic driver mutation. The gene discussed is MAP2K7; the disease is cancer.